Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Reports Sutent Safe And Effective In Asians, Forges Alliances With Major Asian Oncology Centers

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer may draw on Sutent research centers for trials on other oncology therapies such as axitinib and figitumumab, an insulin growth factor receptor inhibitor.
Advertisement

Related Content

ODAC To Assess Schering's PegIntron and GSK's Votrient In October
As Merger With Wyeth Hangs In The Balance Of Beijing's Hands, Pfizer CEO Tours China To Launch Scholarly Partnerships
Pfizer Korea Signs Development Pact With State KRIBB For Liver and Gastric Cancer Drugs
Pfizer Korea Signs Development Pact With State KRIBB For Liver and Gastric Cancer Drugs
Pfizer’s Business Units Enable It To Be Nimble Even as It Grows

Topics

Advertisement
UsernamePublicRestriction

Register

PS070017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel